Avelumab In Combination Treatments in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (Javelin DLBCL)

Phase 1b/Phase 3 Multicenter Study of Avelumab (MSB0010718C) in Combination Regimens That Include an
Immune Agonist, Epigenetic Modulator, CD20 Antagonist and/or Conventional Chemotherapy in Patients With
Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Category & Conditions:
Cancer
Medicine:
Bavencio (avelumab)
PF-05082566
ClinicalTrials.gov Identifier (NCT):
Protocol ID:
B9991011
Open Plain Language Summary Result:Click here